美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

羅氏控股

50.04

-0.2700-0.54%

盤後：50.110.0674+0.13%16:00 EDT

成交量：101.02萬

成交額：5,066.63萬

市值：3,188.05億

市盈率：19.79

高：50.60

開：50.49

低：49.88

收：50.31

52周最高：60.85

52周最低：35.07

股本：63.71億

流通股本：63.71億

量比：0.51

換手率：0.02%

股息：1.55

股息率：3.10%

每股收益(TTM):2.53

每股收益(LYR):2.14

淨資產收益率：37.27%

總資產收益率：12.94%

市淨率：7.44

市盈率(LYR):23.42

資料載入中...

總覽公司新聞資訊公告

羅氏CEO：我們對未來減肥藥市場機遇的預期兩年來始終未變

美國CMS公布第三輪Medicare價格談判名單：15款藥物入選，含Part B產品

羅氏肥胖症藥物減肥效果達 22.5%，力圖趕超禮來和諾和諾德

減肥藥賽道殺出重磅玩家！羅氏(RHHBY.US)CT-388減重幅度達18% 峯值銷售或達25億瑞郎

2026年最有價值的管線資產排名

美國法院：阿斯利康、強生、輝瑞、羅氏等製藥商必須面對援助伊拉克恐怖組織的指控

美股異動丨減肥藥概念股上漲，禮來升逾5%創新高

2025醫藥「10大敗局」：百濟、羅氏、GSK、諾和諾德等盡折戟

美國官員稱與安進、施貴寶、羅氏旗下基因泰克、吉利德、葛蘭素史克、默沙東、諾華、賽諾菲和博瑞諾的交易

歐洲股市在聯儲局決策前保持穩定交易員關注政策走向的線索

环球市场播报

羅氏控股新型乳腺癌藥物研究結果積極，股價上漲

減肥藥概念走強，GPCR升逾5%，諾和諾德升逾4%

老虎资讯综合

羅氏(RHHBY.US)新藥提振股價創28年月度最佳！投資者回歸價值股助力醫療保健板塊「集體狂歡」

羅氏(RHHBY.US)莫妥珠單抗皮下注射製劑獲批上市

羅氏控股逆勢飆升9%！此前其口服藥物被證實能有效控制乳腺癌

老虎资讯综合

羅氏(RHHBY.US)「奧妥珠單抗」獲批治療狼瘡性腎炎

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/RHHBY/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"羅氏控股","latestPrice":50.04,"timestamp":1775851200000,"preClose":50.31,"halted":0,"volume":1010190,"hourTrading":{"tag":"盘后","latestPrice":50.1074,"preClose":50.04,"latestTime":"16:00 EDT","volume":33754,"amount":1691322.4836000002,"timestamp":1775851256588,"change":0.0674,"changeRate":0.001347,"amplitude":0.001347},"delay":15,"changeRate":-0.005366726296958917,"floatShares":6371000000,"shares":6371000000,"eps":2.528533,"marketStatus":"休市中","change":-0.27,"latestTime":"04-10 16:00:56 EDT 延時","open":50.49,"high":50.6,"low":49.88,"amount":50666266.293099895,"amplitude":0.014311,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.528533,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":50.31,"volumeRatio":0.5116515071136898},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6371000000,"roa":"12.94%","roe":"37.27%","lyrEps":2.136203,"volumeRatio":0.5116515071136898,"shares":6371000000,"dividePrice":1.55216,"high":50.6,"amplitude":0.014311,"preClose":50.31,"low":49.88,"week52Low":35.07,"pbRate":"7.44","psRate":"3.97","week52High":60.85,"institutionHeld":0.0396,"latestPrice":50.04,"eps":2.528533,"divideRate":0.031018,"volume":1010190,"delay":15,"ttmEps":2.528533,"open":50.49,"prevYearClose":51.57,"prevWeekClose":49.85,"prevMonthClose":49.71,"prevQuarterClose":49.71,"fiveDayClose":49.85,"twentyDayClose":51.93,"sixtyDayClose":53.34,"earningDate":1776873600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2026-04-23","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776931200000,"name":null,"time":"","dateTimestamp":1776916800000,"actualEps":null},{"date":"2026-03-13","symbol":"RHHBY","amount":1.000732,"announcedDate":"2026-02-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-13","defaultRemindTime":1773408600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2026-03-13","currency":"USD","dateTimestamp":1773374400000,"payDate":null},{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"},{"executeDate":"2023-03-16","recordDate":"2023-03-17","paymentDate":"2023-03-27","value":1.2874582,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.375,"sell":0.125,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1775534400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1124091038","title":"羅氏CEO：我們對未來減肥藥市場機遇的預期兩年來始終未變","url":"https://stock-news.laohu8.com/highlight/detail?id=1124091038","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124091038?lang=zh_tw&edition=fundamental","pubTime":"2026-01-29 15:07","pubTimestamp":1769670422,"startTime":"0","endTime":"0","summary":"罗氏控股首席执行官近日明确表示，公司对减肥药物未来市场潜力的展望，在过去两年间始终保持一致。这一表态凸显了该医药巨头对代谢疾病治疗领域长期增长前景的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013425.SGD","SG9999014906.USD","SGXZ51526630.SGD","LU2264538146.SGD","LU2111349929.HKD","LU1061106388.HKD","LU2108987350.USD","LU2746668974.SGD","IE00B4JS1V06.HKD","BK4007","LU2168564222.USD","LU2491049909.HKD","IE00BJJMRX11.SGD","LU0109391861.USD","IE00B1BXHZ80.USD","LU0708995401.HKD","IE00BJJMRY28.SGD","LU0238689110.USD","LU1551013342.USD","BK4585","LU0061475181.USD","BK4599","LU2456880835.USD","LU0320765059.SGD","LU2023251221.USD","SG9999014898.SGD","LU0689472784.USD","LU0683600562.USD","LU1323610961.USD","LU0058720904.USD","LU2106854487.HKD","LU1868837136.USD","BK4516","LU1868836757.USD","LU2087625088.SGD","LU0466842654.USD","LU2361044949.HKD","LU2552382215.SGD","IE0004445239.USD","LU0323591593.USD","LU1093756168.USD","LU2357305700.SGD","IE00B775H168.HKD","LU1069344957.HKD","LU0882574055.USD","LU2552382058.USD","LU2168564495.EUR","LU2361044865.SGD","LU0672654240.SGD","IE00BKPKM429.USD","LU2471134879.HKD","LU2461242641.AUD","SG9999018857.SGD","IE00BN29S564.USD","LU2896262040.SGD","LU0289739699.SGD","LU2168564065.EUR","LU0094547139.USD","LU0256863902.USD","LU0640476718.USD","LU0820561909.HKD","LU1712237335.SGD","SG9999015978.USD","LU2265009873.SGD","IE00B2B36J28.USD","SG9999018865.SGD","LU2237443382.USD","LU2089284900.SGD","IE0009355771.USD","LU1974910355.USD","LU1989771016.USD","LU2168563687.JPY","LU0203201768.USD","LU1623119135.USD","LU2063271972.USD","SGXZ81514606.USD","LU2236285917.USD","LU2028103732.USD","LU2324357040.USD","LU0096364046.USD","SG9999015952.SGD","LU1814569148.SGD","LU2471134952.CNY","LU0354030511.USD","SGXZ31699556.SGD","SG9999014880.SGD","LU2237443549.SGD","LU2112291526.USD","LU0316494557.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1868836914.USD","LU0882574139.USD","LU0823416689.USD","LU0943347566.SGD","LU1064131342.USD","LU1988902786.USD","RHHBY","LU0198837287.USD","IE0005OL40V9.USD","LU2491050154.USD","LU0122379950.USD","LU0354030438.USD","LU1720051017.SGD","LU2211815571.USD","LU2491050071.SGD","LU0471298777.SGD","LU2237443465.HKD","LU2360106947.USD","LU2552382132.HKD","LU0006306889.USD","LU0109394709.USD","IE0004445015.USD","LU2237443978.SGD","SG9999001176.USD","IE00BK4W5M84.HKD","GB00BDT5M118.USD","LU1868837300.USD","LU1280957306.USD","LU0456855351.SGD","IE00B1XK9C88.USD","LU2602419157.SGD","LU2237443895.HKD","LU0256863811.USD","IE00BWXC8680.SGD","LU0225283273.USD","LU0079474960.USD","LU0266013472.USD","LU1720051108.HKD","LU2471134796.USD","LU1917777945.USD","LU0471298694.HKD","LU0210536198.USD","LU2089283258.USD","LU0353189763.USD","LU0823434740.USD","LU2237438978.USD","LU0097036916.USD","LU0417517546.SGD","LU2089984988.USD","SG9999017495.SGD","LU2361045086.USD","SG9999015986.USD","SGXZ99366536.SGD","LU1232071149.USD","LU0106261372.USD","SG9999013999.USD","LU0432979614.USD","SG9999001176.SGD","LU0353189680.USD","IE00BK4W5L77.USD","IE00BKDWB100.SGD","LU1548497426.USD","LU1291159041.SGD","LU2271345857.HKD","IE00BFSS8Q28.SGD","LU0158827948.USD","LU1267930730.SGD","SGXZ57979304.SGD","LU2750360997.AUD","IE0002141913.USD","LU2468319806.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU2471134523.USD","LU0820561818.USD","LU2168564149.EUR","IE00BJJMRZ35.SGD","LU2462157665.USD","LU0320765992.SGD","LU1804176565.USD","SG9999014914.USD","BK4534","LU0385154629.USD","LU1127390331.HKD","LU2750360641.GBP","LU2237443622.USD","IE00B7KXQ091.USD","IE00BJLML261.HKD","LU0114720955.EUR","LU0203202063.USD","LU2417539215.USD","IE00BFSS7M15.SGD","LU1366192091.USD","LU2746668461.USD","LU1057294990.SGD","LU1035775433.USD","LU0158827781.USD","LU1093756325.SGD","LU0823434583.USD","IE00B4R5TH58.HKD","SG9999015945.SGD","BK4588","LU0787776722.HKD","LU0889565916.HKD","LU0786609619.USD","BK4581","LU0234572021.USD","LU1868836591.USD","BK4533","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606671475","title":"美國CMS公布第三輪Medicare價格談判名單：15款藥物入選，含Part B產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2606671475","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606671475?lang=zh_tw&edition=fundamental","pubTime":"2026-01-28 21:26","pubTimestamp":1769606804,"startTime":"0","endTime":"0","summary":"1月27日，美国医疗保险与医疗补助服务中心公布第三轮《通胀削减法案》药品价格谈判名单，共15款药物。据CMS称，这批药品在2024年11月至2025年10月期间，在Medicare Part B和Part D的总支出约为270亿美元，期间共有180万患者使用了这15种药品。虽然IRA首轮筛选出的10种药物以及去年价格谈判达成的15种药物均由药房配发并纳入Medicare Part D的报销范围，但最新的15种药物名单中包含一些纳入Medicare Part B报销范围的由医生用药的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128214629953ec296&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128214629953ec296&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RHHBY","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0738911758.USD","LU0154236417.USD","GSK","BK4007","LU2346227817.USD","BK4585","LU1894683348.USD","LLY","UCB","LU1003077747.HKD","BK4208","LU2637428348.USD","BK4599","TAK","BK4532","ABBV","BMY","NVS","LU1093756168.USD","LU2500361329.USD","LU0553294199.USD","BK4588","LU1093756325.SGD","LU0661504455.SGD","NVO","GILD","LU0545039389.USD","LU1894683264.USD","LU0949170772.SGD","JNJ","MRK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2606481788","title":"羅氏肥胖症藥物減肥效果達 22.5%，力圖趕超禮來和諾和諾德","url":"https://stock-news.laohu8.com/highlight/detail?id=2606481788","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606481788?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 18:41","pubTimestamp":1769510513,"startTime":"0","endTime":"0","summary":"更新 3-罗氏肥胖症药物减肥效果达 22.5%，力图赶超礼来和诺和诺德罗氏肥胖症药物第二阶段试验显示体重减轻 22.5%罗氏致力于在价值 1,500 亿美元的肥胖症市场上追赶礼来在拥挤的市场中，投资者对 CT-388 的结果反应冷淡增加了要点，导语段增加了上下文，全文增加了细节，第12-13段增加了罗氏公司查克拉瓦西的评论。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL4S3YS0Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2602419157.SGD","IE00B4R5TH58.HKD","IE00BN29S564.USD","LU0079474960.USD","LU2360106947.USD","LU2896262040.SGD","IE00BFSS8Q28.SGD","IE00BJJMRY28.SGD","LU0094547139.USD","LU1366192091.USD","LU0203202063.USD","LU2237443978.SGD","BK4516","BK4581","IE00B1XK9C88.USD","LU2462157665.USD","LU2168564065.EUR","IE00BJT1NW94.SGD","LU0672654240.SGD","SGXZ81514606.USD","LU2361044865.SGD","IE00BWXC8680.SGD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0323591593.USD","LU0640476718.USD","LU0823434583.USD","GB00BDT5M118.USD","LU2264538146.SGD","SGXZ51526630.SGD","LU0787776722.HKD","LU0354030438.USD","SG9999013999.USD","LU0234572021.USD","LU1035775433.USD","RHHBY","IE00BJJMRZ35.SGD","LU0820561818.USD","LU2746668974.SGD","IE0004445239.USD","LU1712237335.SGD","SG9999017495.SGD","LU2491049909.HKD","LU0109391861.USD","SG9999001176.SGD","LU2237443895.HKD","IE00B4JS1V06.HKD","LU0354030511.USD","LU1023059063.AUD","LU1917777945.USD","LU1868836591.USD","LU2063271972.USD","LU1064131342.USD","LU1868836757.USD","LU2028103732.USD","LU2168564149.EUR","IE00BFSS7M15.SGD","LU0882574139.USD","LU1804176565.USD","LU2552382132.HKD","IE00BK4W5L77.USD","LU0097036916.USD","BK4007","LU1548497426.USD","LU0823434740.USD","LU2357305700.SGD","SG9999014906.USD","LU0238689110.USD","LU0786609619.USD","SG9999015945.SGD","LU2265009873.SGD","SG9999018865.SGD","LU1983299246.USD","LU1988902786.USD","LU0471298694.HKD","SG9999015986.USD","LU0158827781.USD","LU0320765059.SGD","LU1069344957.HKD","LU0320765992.SGD","LU1868837300.USD","IE00BJJMRX11.SGD","BK4533","IE00B1BXHZ80.USD","LU0289739699.SGD","LU2168564222.USD","LU2237443465.HKD","LU2471134879.HKD","IE0005OL40V9.USD","LU2211815571.USD","LU0106261372.USD","LU2023251221.USD","LU2471134952.CNY","SG9999014914.USD","SG9999015978.USD","LU1868837136.USD","IE0009355771.USD","LU2087625088.SGD","LU1551013425.SGD","LU2106854487.HKD","IE00B2B36J28.USD","LU1061106388.HKD","LU2236285917.USD","SG9999014880.SGD","LU2237443622.USD","LU0096364046.USD","LU2089283258.USD","LU0820561909.HKD","LU1989771016.USD","SG9999001176.USD","LU2271345857.HKD","LU0158827948.USD","LU0882574055.USD","BK4599","SG9999018857.SGD","LU0316494557.USD","SG9999014898.SGD","IE0002141913.USD","IE0004445015.USD","LU2750360641.GBP","IE00BJLML261.HKD","LU2468319806.SGD","SG9999015952.SGD","LU2471134523.USD","LU0203201768.USD","LU0683600562.USD","LU0708995401.HKD","LU0061475181.USD","LU0225283273.USD","LU0266013472.USD","LU0385154629.USD","LU0943347566.SGD","LU0058720904.USD","LU2750360997.AUD","LU2168563687.JPY","LU1280957306.USD","LU1267930730.SGD","LU2471134796.USD","LU1127390331.HKD","LU2168564495.EUR","LU2324357040.USD","LU2491050071.SGD","LU2112291526.USD","LU1057294990.SGD","LU0471298777.SGD","LU0889565916.HKD","LU1814569148.SGD","LU0006306889.USD","LU1323610961.USD","LU1551013342.USD","LU1868836914.USD","LU0823416689.USD","LU1093756325.SGD","BK4585","LU0109394709.USD","LU1720051017.SGD","LU2461242641.AUD","LU0456855351.SGD","LU0256863811.USD","LU1720051108.HKD","LU2108987350.USD","LU0689472784.USD","LU2361045086.USD","LU2089984988.USD","LU0417517546.SGD","LU2111349929.HKD","LU2491050154.USD","SGXZ57979304.SGD","LU2089284900.SGD","LU2237438978.USD","LU2746668461.USD","LU2552382058.USD","LU0353189680.USD","LU1623119135.USD","LU2023250504.SGD","LU0256863902.USD","LU0466842654.USD","LU0198837287.USD","LU2417539215.USD","LU1974910355.USD","BK4534","IE00B7KXQ091.USD","LU0353189763.USD","LU2237443549.SGD","LU2552382215.SGD","LU1093756168.USD","LU0432979614.USD","SGXZ31699556.SGD","LU2361044949.HKD","LU0114720955.EUR","LU1232071149.USD","BK4588","LU2456880835.USD","LU0122379950.USD","IE00BK4W5M84.HKD","IE00B775H168.HKD","SGXZ99366536.SGD","IE00BKDWB100.SGD","LU2237443382.USD","IE00BKPKM429.USD","LU0210536198.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606201274","title":"減肥藥賽道殺出重磅玩家！羅氏(RHHBY.US)CT-388減重幅度達18% 峯值銷售或達25億瑞郎","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201274","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606201274?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 16:36","pubTimestamp":1769502984,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏宣布，在一项中期试验中，接受其试验性注射减肥药物CT-388的肥胖症患者比接受安慰剂的肥胖症患者多减重18%。这项收购也标志着罗氏正式回归GLP-1领域。然而，到2011年，罗氏因其副作用而放弃了该候选药物。罗氏最新公布的试验结果显示，第48周，接受CT-388治疗的肥胖或超重受试者，体重最大降幅达到18.3%。罗氏表示，将在本季度启动后期试验。该行预计，罗氏最早将于2028年推出该药物，并估计其峰值销售额可能达到25亿瑞士法郎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY","MSFmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606279517","title":"2026年最有價值的管線資產排名","url":"https://stock-news.laohu8.com/highlight/detail?id=2606279517","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606279517?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 10:37","pubTimestamp":1769481473,"startTime":"0","endTime":"0","summary":"通过对医药开发管线进行系统性的NPV排名，能够以前瞻性的财务视角剖析各大药企的战略底牌。当前处于III期，2026年将公布多项顶线数据。临床推进节奏已经很清晰：诺和公开计划在2026年第一季度启动口服与皮下制剂的III期项目。2026年的临床读数将直接决定这条机制路线能否兑现“更安全抗凝”的差异化主张。公司披露的给药方案为每周皮下注射600 mg，最长治疗52周。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127104114a6b0efbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260127104114a6b0efbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861220033.SGD","BK4585","LU0348723411.USD","LU0724618433.USD","AMGN","LU1861215975.USD","04332","BK4588","ROIV","LU1093756168.USD","APGE","BMY","IMVT","LU2357305700.SGD","BK4141","LU0124384867.USD","IE00BFMHRM44.USD","LU1093756325.SGD","LU1548497426.USD","RVMD","JNJ","BK4007","IE00BZ199S13.USD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU2360107325.USD","LU1854104046.USD","BK4532","BK4599","BK4512","IE00BKVL7J92.USD","BK4605","LU1854103824.USD","IE00BD6J9T35.USD","LU1861214812.USD","LU2298322129.HKD","NVO","RHHBY","LU1720051108.HKD","LU1861219969.SGD","LU1978683503.SGD","LLY","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2605893072","title":"美國法院：阿斯利康、強生、輝瑞、羅氏等製藥商必須面對援助伊拉克恐怖組織的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=2605893072","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605893072?lang=zh_tw&edition=fundamental","pubTime":"2026-01-24 07:13","pubTimestamp":1769209992,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4550","LU2430703251.USD","LU0170899867.USD","IE00BVYPNV92.GBP","LU1585245621.USD","LU1674673428.USD","LU2089984988.USD","LU1718418525.SGD","IE00BBT3K403.USD","LU1894683348.USD","IE00BN8TJ469.HKD","SG9999002232.USD","IE00BVYPNW00.USD","LU0985481810.HKD","PFE","LU0225284248.USD","LU1267930813.SGD","LU0321505439.SGD","JNJ","LU0321505868.SGD","LU0689626769.HKD","IE00B7SZLL34.SGD","SG9999001176.USD","BK4532","LU2505996681.GBP","SG9999011175.SGD","LU0320765646.SGD","LU1778281490.HKD","LU2236285917.USD","LU0912757837.SGD","LU2430703095.HKD","LU1261432733.SGD","LU1244550577.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","IE0009355771.USD","IE00B2B36J28.USD","LU2471134796.USD","LU1929549753.HKD","IE00BFXG1179.USD","IE00BDGV0183.EUR","IE00BGHQF631.EUR","BK4585","LU2602419157.SGD","IE0034235303.USD","LU1066051225.USD","LU2471134952.CNY","LU0345770308.USD","LU1430594728.SGD","LU2133065610.SGD","LU0058720904.USD","LU0432979614.USD","IE00B1BXHZ80.USD","SG9999003800.SGD","LU1244550494.USD","LU0456855351.SGD","LU1162221912.USD","LU1883839398.USD","IE0002270589.USD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0985320562.USD","LU0234572021.USD","LU0122379950.USD","LU1732800096.USD","IE00BZ1G4Q59.USD","LU2417539215.USD","IE00B3T34201.USD","LU2471134879.HKD","BK4599","LU0345770993.USD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU0683600562.USD","LU1732799900.SGD","LU2129689431.USD","LU2462157665.USD","LU1674673691.USD","IE00BJT1NW94.SGD","LU1829250122.USD","LU0345769128.USD","LU0466842654.USD","LU1059921491.USD","LU0640476718.USD","BK4581","LU1066051498.USD","LU1280957306.USD","LU2430703178.SGD","LU0234570918.USD","LU2750360997.AUD","LU1061106388.HKD","IE00BLSP4239.USD","LU2750360641.GBP","BK4588","LU0889565916.HKD","BK4504","LU2129689605.HKD","LU2456880835.USD","LU2505996509.AUD","LU0114720955.EUR","LU1032955483.USD","BK4007","IE000M9KFDE8.USD","LU0124676726.USD","SG9999001440.SGD","LU1894683264.USD","LU0098860793.USD","LU0345769631.USD","LU0792757196.USD","LU1023059063.AUD","LU2129689514.USD","IE00BKVL7J92.USD","SGXZ57979304.SGD","LU2468319806.SGD","BK4534","LU0320765992.SGD","IE0002141913.USD","LU1221951129.SGD","BK1574","LU2592432038.USD","AZN","IE00B19Z3B42.SGD","BK4559","LU0795875086.SGD","LU1506573853.SGD","LU1244550221.USD","BK4533","LU1221951046.USD","LU0203345920.USD","IE00B3PB1722.GBP","LU2471134523.USD","LU0795875169.SGD","IE00B42XCP33.USD","BK4592","LU0306807586.USD","IE00BLSP4452.SGD","BK4568","LU0787776722.HKD","LU0203347892.USD","LU0306806265.USD","LU2347655156.SGD","LU0109394709.USD","LU1935042991.SGD","LU1074936037.SGD","LU0225771236.USD","SG9999013999.USD","LU2112291526.USD","LU1057294990.SGD","SG9999001176.SGD","IE00B4R5TH58.HKD","BK1191","LU1914381329.SGD","LU1496350502.SGD","LU1196500208.SGD","LU1032466523.USD","LU1066051811.HKD","RHHBY","IE00B19Z3581.USD","LU0889566641.SGD","LU0070217475.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601235804","title":"美股異動丨減肥藥概念股上漲，禮來升逾5%創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2601235804","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601235804?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 23:18","pubTimestamp":1767799100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b2662d3ff1dff9c19973bc9c47bc6f94","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0320765059.SGD","LU0823416689.USD","LU2112291526.USD","SGXZ99366536.SGD","LU2063271972.USD","LU2468319806.SGD","IE00BK4W5L77.USD","LU0787776722.HKD","LU2471134523.USD","LU2237443549.SGD","LU1551013342.USD","IE00B1XK9C88.USD","LU1023059063.AUD","SG9999001176.SGD","NVO","IE00BKDWB100.SGD","LU0786609619.USD","LU0006306889.USD","LU2357305700.SGD","LU1989771016.USD","BK4599","BK4581","LU0943347566.SGD","LU2237438978.USD","LU0266013472.USD","LU1983299246.USD","SGXZ81514606.USD","IE00BK4W5M84.HKD","LU0106261372.USD","LU0203201768.USD","LU0353189680.USD","LU2236285917.USD","BK4516","LU2750360641.GBP","LU2471134796.USD","LU2106854487.HKD","LU0094547139.USD","IE00BJJMRX11.SGD","IE00BJT1NW94.SGD","LU1814569148.SGD","LU0234572021.USD","LU2491049909.HKD","IE00BWXC8680.SGD","LU2417539215.USD","LU2552382132.HKD","SG9999017495.SGD","LU2168564222.USD","LU0820561909.HKD","LU0385154629.USD","IE00BKPKM429.USD","IE00B775H168.HKD","LU0316494557.USD","LU1720051108.HKD","LU2746668461.USD","LU1291159041.SGD","SG9999018865.SGD","IE00BJJMRZ35.SGD","LU2023250504.SGD","SG9999018857.SGD","LU2168564495.EUR","LU0823434583.USD","LU1093756325.SGD","SG9999015945.SGD","LU0417517546.SGD","LU1057294990.SGD","LU1868836591.USD","RHHBY","LU1868837136.USD","LU2456880835.USD","LU0323591593.USD","LU0198837287.USD","LU1551013425.SGD","LU1323610961.USD","LU2552382058.USD","LU2491050071.SGD","BK4588","LU1064131342.USD","IE00B4R5TH58.HKD","LU0689472784.USD","LU2602419157.SGD","LU0353189763.USD","LU1988902786.USD","LU0114720955.EUR","LU0889565916.HKD","LU1267930730.SGD","LU2264538146.SGD","LU1280957306.USD","IE00BFSS8Q28.SGD","LU1232071149.USD","SG9999014906.USD","LU0456855351.SGD","LU0238689110.USD","IE00B7KXQ091.USD","LU0289739699.SGD","LU1035775433.USD","SG9999001176.USD","BK4007","IE00B2B36J28.USD","LU0320765992.SGD","LLY","LU2168564065.EUR","IE00B4JS1V06.HKD","LU0354030511.USD","LU2461242641.AUD","SG9999014880.SGD","LU0097036916.USD","LU1868836914.USD","LU2471134879.HKD","SG9999015986.USD","BK4534","LU0640476718.USD","LU1804176565.USD","LU1868836757.USD","LU2237443465.HKD","LU1061106388.HKD","LU0471298777.SGD","LU1712237335.SGD","IE00BJLML261.HKD","LU2361044949.HKD","SGXZ57979304.SGD","LU1868837300.USD","LU2211815571.USD","LU1093756168.USD","LU1366192091.USD","LU2168563687.JPY","IE0009355771.USD","LU0823434740.USD","LU0708995401.HKD","LU0061475181.USD","LU0096364046.USD","IE00BFSS7M15.SGD","IE0002141913.USD","LU2746668974.SGD","IE00BFTCPJ56.SGD","LU2237443978.SGD","LU0820561818.USD","IE0004445015.USD","LU0672654240.SGD","LU0203202063.USD","LU0882574139.USD","GB00BDT5M118.USD","LU0122379950.USD","AMGN","BK4585","LU0683600562.USD","SG9999015978.USD","LU0109391861.USD","LU0432979614.USD","LU2491050154.USD","SGXZ31699556.SGD","SG9999015952.SGD","LU2324357040.USD","BK4533","LU0058720904.USD","LU0256863811.USD","LU0256863902.USD","IE00B1BXHZ80.USD","IE0004445239.USD","LU1720051017.SGD","SG9999014898.SGD","LU1917777945.USD","04332","LU0354030438.USD","LU0109394709.USD","LU2168564149.EUR","SGXZ51526630.SGD","SG9999014914.USD","LU1127390331.HKD","LU2108987350.USD","LU0466842654.USD","LU2360106947.USD","LU0882574055.USD","LU1974910355.USD","LU1623119135.USD","LU2471134952.CNY","LU2237443622.USD","LU1548497426.USD","IE00BJJMRY28.SGD","IE00BN29S564.USD","LU2089984988.USD","LU2237443382.USD","LU2237443895.HKD","LU1069344957.HKD","LU2750360997.AUD","LU2265009873.SGD","LU2087625088.SGD","SG9999013999.USD","IE0005OL40V9.USD","LU2361044865.SGD","LU2552382215.SGD","LU2361045086.USD","LU0471298694.HKD","LU2462157665.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595799618","title":"2025醫藥「10大敗局」：百濟、羅氏、GSK、諾和諾德等盡折戟","url":"https://stock-news.laohu8.com/highlight/detail?id=2595799618","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595799618?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 17:36","pubTimestamp":1767087415,"startTime":"0","endTime":"0","summary":"即将过去的2025年，生物医药研发失败的暗礁轮廓格外清晰。这一结果是继罗氏公司semorinemab和艾伯维公司tilavonemab失败后，对tau蛋白免疫治疗领域的又一次重大打击。2025年8月，其在镰状细胞病的一项后期研究中宣告失败。2017年3月，该药首次在美国获批上市，2025年3月在中国获批上市。与此同时，2025年年末，罕见病药物研发领域再传失败案例。在精神神经领域，百时美施贵宝被寄予厚望的Cobenfy遭遇重挫。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230180842a489e0d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230180842a489e0d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK","LU1093756168.USD","BK4588","LU1829250122.USD","BK4007","BK4599","06160","BK4585","GSK.UK","LU0154236417.USD","BK4532","NVO","PFE","RHHBY","LU1093756325.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1190397083","title":"美國官員稱與安進、施貴寶、羅氏旗下基因泰克、吉利德、葛蘭素史克、默沙東、諾華、賽諾菲和博瑞諾的交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1190397083","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190397083?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 03:22","pubTimestamp":1766172127,"startTime":"0","endTime":"0","summary":"美国官员称与安进、施贵宝、罗氏旗下基因泰克、吉利德、葛兰素史克、默沙东、诺华、赛诺菲和博瑞诺的交易","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU0320765489.SGD","LU0098860793.USD","LU1035777561.USD","SGXZ57979304.SGD","LU1989772923.USD","LU1162221912.USD","IE0034235071.USD","LU1261432733.SGD","LU2112291526.USD","LU1989771016.USD","SG9999001176.SGD","LU2125154935.USD","LU1201861249.SGD","LU1674673428.USD","BK4550","SG9999015358.SGD","LU0868494617.USD","SG9999014559.SGD","IE00BFXG1179.USD","LU2361044865.SGD","LU0882574055.USD","BK4532","LU1061106388.HKD","LU1699723380.USD","SG9999002232.USD","SG9999014575.USD","LU0980610538.SGD","LU1093756325.SGD","LU2023250843.SGD","BIIB","SG9999013999.USD","LU1066051498.USD","LU0061475181.USD","LU1291159041.SGD","SG9999001176.USD","IE0002270589.USD","SNY","LU1941712348.USD","LU0130102774.USD","BK5011","LU1116320737.USD","IE00BKVL7J92.USD","LU0114720955.EUR","BK4139","BK4581","LU0477156953.USD","LU0265550359.USD","LU1718418525.SGD","IE00B1BXHZ80.USD","LU1839511570.USD","LU0122379950.USD","LU0648001328.SGD","LU0985481810.HKD","LU1400636574.HKD","LU1481600234.SGD","IE0002141913.USD","BK4585","BK4568","LU0320765992.SGD","BK4533","SG9999015978.USD","BK4583","IE000M9KFDE8.USD","LU1066053197.SGD","LU0058720904.USD","LU0965509010.AUD","LU1302929846.USD","LU1037948897.HKD","LU0203345920.USD","LU0321505439.SGD","LU0208291251.USD","SG9999015986.USD","LU1868836591.USD","LU2461242641.AUD","LU0985320562.USD","IE00BLSP4239.USD","LU2089984988.USD","LU0889565916.HKD","LU1571399168.USD","LU1487256676.USD","LU1934455277.USD","LU0266013472.USD","LU1400636491.USD","IE00BQJZX424.USD","SG9999015945.SGD","LU1481599808.USD","LU1066051811.HKD","LU1069347547.HKD","LU0965508806.USD","LU0971552673.USD","LU1868837300.USD","IE00B2B36J28.USD","LU2125154778.USD","LU0006306889.USD","BK4566","LU0965509101.SGD","IE00BZ1G4Q59.USD","LU0109981661.USD","LU0320765646.SGD","LU1670710588.SGD","LU1868836757.USD","GSK","MRK","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0225284248.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU2106854487.HKD","LU0289739699.SGD","BK4578","IE00BLSP4452.SGD","LU0211331839.USD","LU0234570918.USD","LU0106261372.USD","LU0306806265.USD","LU1074936037.SGD","LU1400636657.SGD","LU2023250504.SGD","LU1093756168.USD","SG9999002224.SGD","04332","LU1046248800.SGD","LU2361045086.USD","LU1098665638.USD","LU0109394709.USD","IE00B3T34201.USD","LU0456855351.SGD","LU1941712264.USD","LU2242646821.SGD","LU1989772840.SGD","LU1670756490.USD","BK4534","IE00B19Z3581.USD","LU2468319806.SGD","LU2324357040.USD","LU0545562505.USD","LU1983299246.USD","LU0130517989.USD","LU2360032135.SGD","LU0267386448.USD","LU1066051225.USD","LU0265550946.USD","LU0861579265.USD","LU1934455863.HKD","LU1670711123.USD","LU0823416689.USD","IE00BBT3K403.USD","LU0575583348.USD","LU1868836914.USD","LU1670710661.SGD","LU2133065610.SGD","LU0096364046.USD","BK4588","LU1057294990.SGD","AMGN","LU1023059063.AUD","LU1309081286.SGD","LU2361044949.HKD","LU1917777945.USD","IE00BJJMRZ35.SGD","IE00BWDBJ516.SGD","LU2242652126.USD","LU1015430645.USD","LU1064927863.SGD","LU1430594728.SGD","LU1585245621.USD","LU1934455194.USD","IE00BN8TJ469.HKD","LU1778281490.HKD","NVS","LU1035773651.USD","LU1032466523.USD","SG9999001440.SGD","BK4007","IE00BSNM7G36.USD","LU2087621335.USD","LU0321505868.SGD","BK4516","LU1929549753.HKD","IE00BJT1NW94.SGD","IE00B7SZLL34.SGD","LU0306807586.USD","LU0965509283.SGD","GILD","IE00B4R5TH58.HKD","LU1974910355.USD","LU0237698245.USD","LU0203347892.USD","LU0225771236.USD","SG9999014542.SGD","RHHBY","LU1228905037.USD","SG9999015952.SGD","LU1323610961.USD","LU0161305163.EUR","SG9999014567.USD","LU0238689110.USD","LU0971552830.HKD","LU0234572021.USD","LU1202635105.USD","LU1645745479.HKD","BMY","LU0070302665.USD","LU1674673691.USD","LU1228905540.USD","BK4599","SG9999015341.SGD","LU1868837136.USD","LU1116320901.HKD","LU1670711040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590534908","title":"歐洲股市在聯儲局決策前保持穩定 交易員關注政策走向的線索","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534908","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534908?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 01:57","pubTimestamp":1765389420,"startTime":"0","endTime":"0","summary":"在美联储周三公布备受关注的利率决策之前，欧洲股市保持稳定，市场担忧全球货币宽松周期可能接近尾声。　　斯托克欧洲600指数收盘几乎持平。该国国民议会通过了明年的社保法案，从而避免了另一场潜在的政府危机。　　欧洲股市仍在接近11月份创下的纪录高位附近交易，不过在全球央行货币宽松步伐引发担忧之际，动能有所减弱。交易员对美联储周三几乎板上钉钉的降息之后未来的政策路径感到愈发不安。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/world/2025-12-11/doc-inhaiyww8502676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","UPRO","ABVX","TLTW","AEG","SDS",".SPX","BK4550","IVV","SPXU","BK4534","MESmain","ESmain","TMF","SSO","BK4559","OEX","BK4588","RHHBY","BK4504","SH","OEF","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1179329229","title":"羅氏控股新型乳腺癌藥物研究結果積極，股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=1179329229","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179329229?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 23:32","pubTimestamp":1765380752,"startTime":"0","endTime":"0","summary":"罗氏控股的股价在周三上涨了2%，原因是这家瑞士制药公司报告了一项新型试验乳腺癌药物的积极研究结果。\n该药物giredestrant在一项针对某种类型早期乳腺癌患者的研究中，与传统疗法相比，降低了30%的死亡风险或侵袭性疾病的发生。此次三期研究共招募约4,100名患者。\n如果监管机构批准该药物并上市，它可能会成为一个巨大的销售增长点，因为该药物承诺在多年内为这种基础于内分泌的乳腺癌治疗带来第一次显著的进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169452002","title":"減肥藥概念走強，GPCR升逾5%，諾和諾德升逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169452002","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169452002?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 23:26","pubTimestamp":1765380382,"startTime":"0","endTime":"0","summary":"罗氏控股涨超3%，礼来跟涨。","market":"us","thumbnail":"https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8c3694a08f44a67f8ee972cef2b11b95","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LLY","GPCR","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588723159","title":"羅氏(RHHBY.US)新藥提振股價創28年月度最佳！投資者回歸價值股助力醫療保健板塊「集體狂歡」","url":"https://stock-news.laohu8.com/highlight/detail?id=2588723159","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588723159?lang=zh_tw&edition=fundamental","pubTime":"2025-12-01 17:37","pubTimestamp":1764581822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，对罗氏旗下一款实验性乳腺癌药物的乐观情绪以及令人鼓舞的试验结果推动该公司股价创下自1997年以来的最佳月度表现。据悉，11月18日，罗氏宣布乳腺癌III期lidERA研究取得积极结果。Giredestrant耐受性良好，不良事件与其已知安全性一致，未发现新的安全性信号。受此消息提振，罗氏的股价在11月飙升19%，引来市场关注。这也是推动罗氏股价上涨的一个重要原因。从个股来看，除了罗氏还有其他医疗保健股表现优异。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"罗氏(RHHBY.US)新药提振股价创28年月度最佳！投资者回归价值股助力医疗保健板块“集体狂欢”","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","03165","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584802941","title":"羅氏(RHHBY.US)莫妥珠單抗皮下注射製劑獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2584802941","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584802941?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 21:06","pubTimestamp":1763557606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月19日，罗氏宣布Lunsumio皮下注射制剂的有条件上市许可申请已获欧盟委员会批准，用于治疗接受过二线及以上系统治疗的复发或难治性(R/R)滤泡淋巴瘤成人患者。莫妥珠单抗是罗氏开发的一款靶向CD20和CD3的T细胞衔接器双抗，通过靶向激活并重定向患者现有的T细胞，释放细胞毒性蛋白进入B细胞，从而激活并消除目标B细胞。莫妥珠单抗静脉注射制剂于2022年6月在欧盟获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)莫妥珠单抗皮下注射制剂获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148672489","title":"羅氏控股逆勢飆升9%！此前其口服藥物被證實能有效控制乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148672489","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148672489?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 23:11","pubTimestamp":1763478690,"startTime":"0","endTime":"0","summary":"11月18日，罗氏控股逆势飙升9%！此前其口服药物被证实能有效控制乳腺癌。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e193b88a792ba19bd30bacf372e810a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"罗氏控股逆势飙升9%！此前其口服药物被证实能有效控制乳腺癌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2576852194","title":"羅氏(RHHBY.US)「奧妥珠單抗」獲批治療狼瘡性腎炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2576852194","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576852194?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 21:06","pubTimestamp":1760965614,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月20日，罗氏宣布奥妥珠单抗获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎成人患者。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY研究的积极结果。与此同时，奥妥珠单抗组的补体水平相较于标准治疗组也实现了具有临床意义的改善，并且抗dsDNA抗体、疾病活动度和炎症标志物水平也有所降低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)“奥妥珠单抗”获批治疗狼疮性肾炎","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}